

免疫治療研究部 論文(2017年)

【英語論文】

原著論文

1. Akiyama Y, Nonomura C, Ashizawa T, Iizuka A, Kondou R, Miyata H, Sugino T, Mitsuya K, Hayashi N, Nakasu Y, Asai A, Ito M, Kiyohara Y, Yamaguchi K. The anti-tumor activity of the STAT3 inhibitor STX-0119 occurs via promotion of tumor-infiltrating lymphocyte accumulation in temozolomide-resistant glioblastoma cell line. *Immunol Lett* 2017;190:20-25.
2. Ashizawa T, Iizuka A, Nonomura C, Kondou R, Maeda C, Miyata H, Sugino T, Mitsuya K, Hayashi N, Nakasu Y, Maruyama K, Yamaguchi K, Katano I, Ito M, Akiyama Y. Antitumor Effect of Programmed Death-1 (PD-1) Blockade in Humanized the NOG-MHC Double Knockout Mouse. *Clin Cancer Res.* 2017;23(1):149-158.
3. Miyata H, Ashizawa T, Iizuka A, Kondou R, Nonomura C, Sugino T, Urakami K, Asai A, Hayashi N, Mitsuya K, Nakasu Y, Yamaguchi K, Akiyama Y. Combination of a STAT3 inhibitor and an mTOR inhibitor against a temozolomide-resistant glioblastoma cell line. *Cancer Genomics Proteomics.* 2017;14(1):83-91.

【共同研究 英語論文】

原著論文

1. Kikuchi T, Shimizu H, Akiyama Y, Taniguchi T. In situ delivery and production system of trastuzumab scFv with bifidobacterium. *Biochem Biophys Res Commun* 2017;493(1):306-312.
2. Kiyohara Y, Yoshikawa S, Otsuka M, Kondou R, Iizuka A, Nonomura C, Ohshima K, Urakami K, Kusuhara M, Nagashima T, Sugino T, Yamaguchi K, Akiyama Y. Melanoma patient response to nivolumab treatment for metastatic lung lesions; Multi-OMICS analysis in project HOPE. *J Dermatol.* 2017;44(10):1156-1159.
3. Yoshikawa S, Kiyohara Y, Otsuka M, Kondou R, Nonomura C, Miyata H, Iizuka A, Ohshima K, Urakami K, Nagashima T, Kusuhara M, Sugino T, Mochizuki T, Yamaguchi K, Akiyama Y. Multi-Omics profiling of patients with melanoma treated with nivolumab in project HOPE. *AntiCancer Res.* 2017;37(3):1321-1328.